Regeneron Pharmaceuticals (REGN) opened its latest reporting season with Q4 2025 revenue of US$3.9 billion and basic EPS of US$8.21, setting the stage for how investors assess Q1 2026 with the shares trading around US$686.83. Over the last year, the company has seen quarterly revenue move between US$3.0 billion and US$3.9 billion, while basic EPS has ranged from US$7.58 to US$14.09. This gives a clear view of how the top and bottom lines have tracked together through 2025 and into the new fiscal year. Taken together, those trends put the spotlight on how Q1 margins are holding up and what that might indicate about earnings power.

See our full analysis for Regeneron Pharmaceuticals.

With the headline numbers on the table, the next step is to set them against the most common stories around Regeneron to see which narratives the latest results support and which ones the data challenges.

Earnings Growth Turns Positive Against Five Year Slide

• Trailing 12 month earnings growth was 2.1%, compared with a five year average annual decline of 9.7%, and net profit margin sat at 31.4% versus 31.1% a year earlier.
• Bulls point to this shift as early evidence that the long term earnings drag is easing, yet the data also shows only modest movement so far:
  • Trailing 12 month net income is US$4.5b on revenue of US$14.3b, which lines up with the 31.4% margin and suggests profitability is stable rather than dramatically accelerating right now.
  • The bullish view expects earnings to climb to US$7.4b over time, so the current 2.1% growth rate is a starting point rather than clear confirmation of that path.

Bulls argue that this early turn in earnings could be the first step toward the stronger profit ramp they are expecting, especially as more late stage products move through the pipeline and contribute to that US$4.5b earnings base.

🐂 Regeneron Pharmaceuticals Bull Case

Margins Hold While Revenue Growth Trails Market

• Revenue in the latest trailing 12 month period was US$14.3b with net profit margin at 31.4%, while revenue is forecast to grow about 7.5% per year versus an 11.1% US market forecast.
• Bears highlight this slower top line outlook as a pressure point, especially given reliance on a few major drugs:
  • The 31.4% margin is only slightly above the prior 31.1%, which leaves limited cushion if pricing or volumes for key franchises come under strain from biosimilars or payer pressure.
  • With revenue growth projected below the broader market, the bearish concern is that even solid margins may not fully offset softer sales momentum over time.

Skeptics warn that a 7.5% revenue growth outlook against faster growing peers could make any future margin compression from competition or pricing changes more visible in overall profit trends.

🐻 Regeneron Pharmaceuticals Bear Case

P/E Discount and Big DCF Gap Stand Out

• The shares trade around US$686.83 on a trailing P/E of 15.5x, below the US Biotech industry average of 16.9x and a peer average of 22.9x, while the DCF fair value in the dataset is US$2,020.13 and the single allowed analyst target is US$877.27.
• Supporters of the bullish narrative see this combination of lower P/E and higher value markers as a sign the market is being cautious, yet the figures also set a high bar:
  • The gap between the current price of US$686.83 and the DCF fair value of US$2,020.13 is very large, which means the underlying assumptions on future earnings and margins carry a lot of weight in that model.
  • Even the US$877.27 analyst target sits well above the current price, so if future earnings or revenue growth land closer to the more cautious scenarios, that valuation upside could narrow quickly.

What stands out is that the market price implies a discount to both the industry P/E and the valuation markers in the data, so your view on growth durability and pipeline delivery will probably drive how comfortable you are with that gap.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Regeneron Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of bullish and cautious takes in this article shows how split opinion can be, so it is worth looking through the data yourself and acting while the current setup is fresh in mind. To see exactly what others view as the main positives, check the 4 key rewards.

See What Else Is Out There

Regeneron faces questions around its slower 7.5% revenue growth outlook versus the wider US market and a large gap between trading price and DCF fair value.

If that mix of softer growth expectations and valuation uncertainty gives you pause, compare it with 52 high quality undervalued stocks right now to find companies where pricing and fundamentals may feel more aligned.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.